Lexicon Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Lexicon Pharmaceuticals reports a significant revenue increase driven by milestone payments, alongside a reduced net loss for the first quarter of 2026.
NASDAQ
Lexicon Pharmaceuticals reported a significantly reduced net loss for Q3 2025, driven by a substantial licensing agreement with Novo Nordisk and aggressive cost-cutting measures.
NASDAQ
Lexicon Pharmaceuticals reported a significantly reduced net loss for the six months ended June 30, 2025, driven by a substantial licensing agreement with Novo Nordisk and reduced operating expenses.
NASDAQ
Lexicon Pharmaceuticals announces its Q1 2025 financial results, featuring a licensing agreement with Novo Nordisk for LX9851 and a prepayment of $45 million on its Oxford Term Loans.
NASDAQ
Lexicon Pharmaceuticals reported its third quarter 2024 financial results, showing increased revenue from INPEFA sales and ongoing development of its drug pipeline.
NASDAQ
10-Q: Lexicon Pharmaceuticals Reports Increased Revenue and Losses in Q2 2024, Secures New Office Lease
Lexicon Pharmaceuticals saw a rise in product revenue driven by INPEFA sales, but also experienced increased operating expenses and net losses in the second quarter of 2024.
NASDAQ
Lexicon Pharmaceuticals' first quarter 2024 results show increased revenue from INPEFA sales and a significant capital raise, alongside increased operating expenses.